WASHINGTON, May 22, 2017 /PRNewswire/ -- According to a
new ResMed-sponsored (NYSE:RMD) study, people with treatment-emergent central sleep apnea (CSA) have a significantly greater risk
of terminating positive airway pressure (PAP) treatment. Researchers found that 3.5 percent of patients had CSA during the first
90 days of PAP therapy. The study, Trajectories of Central Sleep Apnea during Continuous Positive Airway Pressure and
Association with Therapy Termination: A Big Data Analysis, was presented today at the 2017 American Thoracic Society
International Conference.
This analysis highlights the importance of:
- Regularly monitoring patients to support adherence to treatment
Untreated sleep apnea increases the risk of other chronic diseases known for being prevalent with sleep apnea,
including drug-resistant hypertension (83 percent), morbid obesity (77 percent), type 2 diabetes (72 percent) and stroke (62
percent)1.
-
Early diagnosis of CSA to minimize risk of therapy termination
Findings from the largest-ever study of patients with treatment-emergent CSA, presented at the April 2017 European Respiratory Society and European Society of Sleep Research conference showed that
switching treatment from continuous positive airway pressure (CPAP) to adaptive servo-ventilation (ASV) therapy2
significantly improved the patient's adherence to therapy. It also showed that those with treatment-emergent CSA who switched
from CPAP to ASV used their therapy longer and had significantly fewer apneas (breathing stoppages or reductions) during
sleep.
"This study provides the most robust view available on the prevalence of CSA in patients on PAP therapy," said Dr.
Carlos Nunez, ResMed's chief medical officer. "The findings in this new research, combined with
the research presented in April 2017, underscore the importance of keeping patients on therapy
through regular monitoring, and rethinking the conventional wisdom on therapeutic options based on each patient's disease
severity."
The new analysis defined three groups among patients with CSA – emergent, persistent and transient – based on whether the
condition was present at the start of therapy or emerged during the first 12 weeks. All three groups showed a significantly
higher risk of terminating their therapy than those without CSA. The risk was highest among the emergent group, whose CSA only
became apparent during treatment, and were 1.7 times more likely to terminate their therapy than those without the condition.
About the Study
The study authors included: Atul Malhotra, University of
California San Diego, United States; Peter Cistulli,
University of Sydney, Australia; and Jean-Louis Pépin, Grenoble Alpes University, France.
A retrospective analysis used anonymous, aggregated telemonitoring data from a U.S. positive airway pressure therapy database,
(ResMed AirView™) and analyzed it for the presence or absence of CSA during CPAP therapy at baseline (week 1) and after 12
weeks.
Session data included weekly values by averaging within each week for each patient. Defined patient groups were: OSA, emergent
CSA, persistent CSA and transient CSA. Groups were compared to identify risk factors for different forms of CSA, and adherence
and therapy termination rates were determined.
Patients with any form of CSA during CPAP were at higher risk of terminating therapy in the first 90 days versus those who did
not develop CSA (hazard ratio 1.7 for emergent CSA, 1.4 for persistent CSA and 1.3 for transient CSA; all p<0.001).
About Central Sleep Apnea
Obstructive sleep apnea (OSA) and central sleep apnea (CSA) are the two most common types of sleep apnea, a condition
that results in repetitive pauses in breathing during sleep. OSA is a sleep disorder in which the throat muscles relax, block the
airways and stop the flow of breath during sleep. CSA is a sleep disorder in which the brain does not transmit the "breathe"
signal to the muscles that control breathing during sleep. In either situation, the lack of oxygen causes the person to wake up
to catch their breath and start breathing again, interrupting continuous sleep. This may occur multiple times in an hour.
In some patients with OSA, CSA may emerge and only become apparent during CPAP therapy. This was recognized in the third
edition of the International Classification of Sleep Disorders and called "treatment-emergent CSA".
About ResMed
ResMed (NYSE: RMD) changes lives with award-winning medical devices and cloud-based software applications that
diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is the
global leader in connected care, with more than 3 million patients remotely monitored every day. Our 5,000-strong team is
committed to creating the world's best tech-driven medical device company – improving quality of life, reducing the impact of
chronic disease, and saving healthcare costs in more than 100 countries. ResMed.com | Facebook | Twitter | LinkedIn
1 References: Gami AS et al. Circulation 2004, O'Keefe and Patterson, Obes Surgery 2004, Logan et al.
J. Hypertension 2001, O'Keeffe T and Patterson EJ. Obes Surg 2004, Einhorn D et al. Endocr Pract 2007, Bassetti C and
Aldrich M. Sleep 1999
2 ASV therapy is contraindicated in patients with chronic, symptomatic heart failure (NYHA 2-4) with reduced left
ventricular ejection fraction (LVEF ≤ 45%) and moderate to severe predominant central sleep apnea.
Contacts:
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/big-data-yields-big-insights-for-treatment-of-central-sleep-apnea-300461209.html
SOURCE ResMed Inc.